Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Radiotherapy offers new treatment option for liver cancer

A novel technique that delivers high doses of radiation to tumours while sparing the surrounding normal tissue shows promise as a curative treatment option for patients with early-stage liver cancer, according to a study published online in the journal Radiology.

Curative treatment options for early-stage hepatocellular carcinoma (HCC), the most common type of liver cancer, include surgery, liver transplantation and radiofrequency ablation.

However, many patients are not candidates for these therapies due to the presence of other conditions.

In addition, these treatments carry significant costs and potential complications.

Radiation segmentectomy (RS) is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours.

The isotope is embedded into tiny beads that are delivered through a catheter into a blood vessel in the liver.

They then travel to the site of the tumour, where they come to rest and deliver their radioactive effect while sparing much of the surrounding healthy tissue.

The procedure's name derives from the fact that surgeons divide the liver into a number of segments.

Using an imaging approach called cone beam CT, interventional radiologists gain a detailed view of the complex liver vasculature and can focus delivery of the Y90 to the relevant segment.

"Cone beam CT has revolutionised our ability to perform segmental injections isolated to very small tumours, sparing the majority of normal tissue," said study senior author Riad Salem, M.D., chief of vascular interventional radiology in the Department of Radiology at the Northwestern University Feinberg School of Medicine in Chicago.

"Before cone beam CT, we had the ability to focus radiation, but not with this level of accuracy."

Dr. Salem and colleagues studied long-term outcomes in 70 early-stage HCC patients who had undergone RS between 2003 and 2016.

They analysed the patients' responses to treatment based on two commonly used sets of criteria.

Based on one criteria, 90 percent of patients showed positive response to the therapy, of which 59 percent showed complete response.

Based on a second criteria, 71 percent achieved positive response, of which 16 percent achieved complete response.

RS controlled the target tumour, slowed the time to disease progression and improved survival outcomes at rates comparable to radiofrequency ablation, surgery and transplantation for early-stage HCC patients.

Almost three-quarters of patients had no progression of cancer in the target tumour five years after treatment.

Median overall survival was 6.7 years, and one-, three-, and five-year survival probabilities were 98 percent, 66 percent and 57 percent, respectively.

One-, three-, and five-year overall survival probability was 100 percent, 82 percent and 75 percent in patients with a baseline tumour size of 3 centimetres or less.

"The results show that we are able to impart curative outcomes to these patients," Dr. Salem said.

"Our numbers with radiation segmentectomy match or outperform those of other curative treatments in terms of tumour control, survival rate and recurrence."

RS is performed on an outpatient basis, is minimally invasive and has a low toxicity profile, Dr. Salem said.

Given the potency of the radiation, RS outperforms transarterial chemoembolisation, another minimally invasive procedure in which cancer-killing drugs are injected into the liver's main artery under imaging guidance and travel to the tumour microvasculature.

Transarterial chemoembolisation has the additional disadvantage of requiring hospitalisation.

The researchers continue to follow the patients from the study group as they work on ways to optimize the treatment.

"We want to see these outcomes validated in patients over the longer term," Dr. Salem said.

"We also want to minimise the time from clinic visit to treatment, and fine-tune dosimetry so that we can find the optimal dose that will kill the tumour. In the right patient setting, RS can be considered curative."

Source: Radiological Society of North America

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation